Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682164 | 0.90 | CYP11B1 (0.43) | CYP11B1CYP11B2ENPP2SIRT2 | |
| SCHEMBL1040045 | 0.87 | CYP11B1 (0.41) | CYP11B1CYP11B2KDM4EENPP2SIRT2 | |
| SCHEMBL28422181 | 0.87 | ADA (0.47) | CYP11B1CYP11B2ENPP2SIRT2 | |
| SCHEMBL693097 | 0.87 | CYP11B1 (0.41) | CYP11B1CYP11B2LMNAL3MBTL1ENPP2 | |
| SCHEMBL8373202 | 0.84 | CYP11B1 (0.39) | CYP11B1CYP11B2ENPP2SIRT2 | |
| SCHEMBL1738160 | 0.84 | AKT1 (0.41) | CYP11B1CYP11B2ENPP2SIRT2ALDH1A1 | |
| SCHEMBL2664184 | 0.83 | KDM4E (0.42) | KDM4ELMNANAPRTP4HTML3MBTL1 | |
| SCHEMBL9489847 | 0.83 | SIRT2 (0.40) | CYP11B1CYP11B2ENPP2SIRT2 | |
| SCHEMBL28415779 | 0.83 | BRD4 (0.40) | CYP11B1CYP11B2ENPP2SIRT2 | |
| SCHEMBL1414901 | 0.83 | SIRT2 (0.40) | CYP11B1CYP11B2L3MBTL1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | claimed |
| US-20160272594-A1 | PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2016-09-22 | — | — | US | claimed |
| CN-103588711-B | Preparation method for medetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO LTD | 2015-04-08 | — | — | CN | claimed |
| CN-103588711-A | Preparation method for medetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO LTD | 2014-02-19 | — | — | CN | claimed |
| WO-2020239999-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| CN-108314654-B | Intermediate for preparing medetomidine and preparation method and application thereof | 山东百诺医药股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9533983-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-03 | — | — | US | disclosed |
| WO-2002030927-A1 | NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2002-04-18 | — | — | WO | disclosed |
| US-6350757-B1 | Beta-carboline compounds | LES LABORATOIRES SERVIER (FR) | 2002-02-26 | — | — | US | disclosed |
| US-6348480-B1 | CALCIUM CHANNEL BLOCKERS AND ANTIINFLAMMATORY AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| US-20010011090-A1 | Pyrazole derivative | ASTELLAS PHARMA INC. (JP) | 2001-08-02 | — | — | US | disclosed |
| EP-1024138-A1 | PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-08-02 | — | — | EP | disclosed |
| EP-0338939-B1 | HISTAMINE DERIVATIVE, PROCESS FOR HIS PREPARATION AND HIS THERAPEUTIC APPLICATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-01-27 | — | — | EP | disclosed |
| US-5034539-A | Histamine derivative, process for preparing it and its therapeutic use | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1991-07-23 | — | — | US | disclosed |
| EP-0338939-A1 | Histamine derivative, process for his preparation and his therapeutic application | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272594-A1 | PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE | AVPR2, TET1, TET2 | CYP11B1 34/4885CYP11B2 31/4885KDM4E 855/4885 |
| US-20010011090-A1 | Pyrazole derivative | RYR1, CACNA1E, RYR2 | CYP11B1 480/4885CYP11B2 555/4885KDM4E 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.